Complement System Antagonists

Featured Inhibitors
Inhibitors (12)
Agonists (2)
Antagonists (2)

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	CNS Neurosci Ther, 2025, 31(1):e70216 Invest Ophthalmol Vis Sci, 2025, 66(5):2 Cell Death Dis, 2023, 14(4):285
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S8931

SB290157 trifluoroacetate

SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.

CNS Neurosci Ther, 2025, 31(1):e70216

Invest Ophthalmol Vis Sci, 2025, 66(5):2

Cell Death Dis, 2023, 14(4):285

E1048

JR14a

JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.